Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Bone and Calcium Disorders
•
Primary Care
Do you recommend the use of Denosumab for osteoporosis management in patients receiving IVIG therapy?
Related Questions
Would you recommend waiting for a low Vitamin D level to correct to goal prior to giving a scheduled Prolia injection when transitioning a patient from Zolendronic acid to Prolia therapy for worsening osteoporosis?
When cinacalcet is used to treat hypercalcemia in primary hyperparathyroidism, does it also normalize low serum phosphorus levels?
Would you order a repeat DEXA scan 1 year later for a kidney transplant patient who had an initial DEXA scan within the first 6 months post-transplant showing osteopenia but no history of fractures, and who has been stable on glucocorticoid-free immunosuppressive therapy?
When do you recommend using trabecular bone score (TBS) for managing osteoporosis?
How do you approach a patient with elevated bone specific ALP (>2X the normal limit), but no other evidence of Paget's disease?
How frequently do you monitor for hypocalcemia in patients on romosozumab?
Does vitamin D supplementation in primary hyperparathyroidism increase the risk of kidney stones?
Are there any concerns with live vaccine innoculation and patients who are on denosumab?
What range of musculoskeletal complaints have you seen with romosozumab use?
Do oral contraceptives lower bone mineral density in women with hypothalamic amenorrhea by lowering IGF-1?
